Polymorphism of the 5-HT transporter and response to antidepressants: Randomised controlled trial

British Journal of Psychiatry

Volumn 198, Issue 6, 2011, Pages 464-471

  Lewis, Glyn ^a   Mulligan, Jean ^a   Wiles, Nicola ^a   Cowen, Philip ^b   Craddock, Nick ^c   Ikeda, Masashi ^c   Grozeva, Detelina ^c   Mason, Victoria ^d   Nutt, David ^e   Sharp, Deborah ^a   Tallon, Debbie ^a   Thomas, Laura ^a   O'Donovan, Michael C ^c   Peters, Tim J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF WORCESTER   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; REBOXETINE; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; GREAT BRITAIN; HOMOZYGOTE; HUMANS; LIFE CHANGE EVENTS; MALE; MIDDLE AGED; MORPHOLINES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957439084     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.082727     Document Type: Article

References (41)

1. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 2000; 177: 292-302.
2. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
3. Prescribing Support Unit. Prescribing Monitoring Report April 2007 - March 2008. Leeds Information Centre for Health and Social Care, 2008.
4. Medical Expenditure Panel Survey. Antidepressants Prescribed by Medical Doctors in Office Based and Outpatient Settings by Specialty for the US Civilian Noninstitutionalized Population, 2002 and 2005. US Agency for Healthcare Research and Quality, 2008.
5. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-30.
6. Laux G, Konig W, Lesch KP, Stein A. Intravenous versus oral treatment of endogenously depressed patients with doxepin - a double-blind study with plasma level determination. Wien Med Wochenschr 1989; 139: 525-9.
7. Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology 2000; 150: 120-2. (Pubitemid 30350822)
8. Murthy NV, Selvaraj S, Cowen P, Bhagwagar Z, Riedel WJ, Peers P, et al. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 2010; 52: 50-4.
9. Serretti A, Kato M, De RD, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-57. (Pubitemid 46328503)
10. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64: 783-92. (Pubitemid 47026374)
11. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 341-51.
12. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 2010; 68: 536-43.
13. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009; 195: 30-8.
14. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AC, Rogers GR, et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339-46. (Pubitemid 38146251)
15. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006; 296: 1609-18. (Pubitemid 44511608)
16. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trial. Lancet 2001; 357: 1191-4. (Pubitemid 32378696)
17. Patsopoulos NA, Tatsioni A, Ioannidis JP. Claims of sex differences: an empirical assessment in genetic associations. JAMA 2007; 298: 880-93. (Pubitemid 47311294)
18. Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, et al. Genetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 2008; 9: 29.
19. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. WHO, 1992.
20. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardised assessment for use by lay interviewers. Psychol Med 1992; 22: 465-86.
21. Lewis G. Assessing psychiatric disorder with a human interviewer or a computer. J Epidemiol Commun Health 1994; 48: 207-10. (Pubitemid 24148410)
22. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
23. Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy 1997; 2: 14-8. (Pubitemid 27077648)
24. Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70. (Pubitemid 13098606)
25. Kirov G, Rees M, Jones I, MacCandless F, Owen MJ, Craddock N. Bipolar disorder and the serotonin transporter gene: a family-based association study. Psychol Med 1999; 29: 1249-54. (Pubitemid 29469315)
26. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, et al. Polymorphism in the serotonin transporter gene associated with susceptibility to major depression. Lancet 1996; 347: 731-3. (Pubitemid 26085649)
27. Lubin JH, Gail MH. On power and sample size for studying features of the relative odds of disease. Am J Epidemiol 1990; 131: 552-66. (Pubitemid 20051751)
28. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environmental interactions: comments on different approaches. Am J Epidemiol 1999; 149: 689-93.
29. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
30. Brookes ST, Whitley E, Egger M, Davey Smith G, Mulheran P, Peters TJ. Subgroup analyses in randomised controlled trials: risks of sub-group specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004; 57: 229-36. (Pubitemid 38456874)
31. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials 2007; 4: 245-53. (Pubitemid 47400532)
32. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374-81. (Pubitemid 41219705)
33. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815-26.
34. Wendland JR, Kruse MR, Cromer KR, Murphy DL. A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. Neuropsychopharmacology 2007; 32: 2543-51. (Pubitemid 350126846)
35. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter- linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163: 48-51. (Pubitemid 43050102)
36. Martin J, Cleak J, Willis-Owen SA, Flint J, Shifman S. Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Mol Psychiatry 2007; 12: 421-2. (Pubitemid 46652459)
37. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61: 734-42. (Pubitemid 46330243)
38. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001; 158: 1843-9. (Pubitemid 33054777)
39. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405: 847-56. (Pubitemid 30407863)
40. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet 2009; 18: 3525-31.
41. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005; 95 (suppl 1): S144-50.